X

Drug Profile

WGc 043

Alternative Names: WGc-043

Latest Information Update: 09 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WestGene Biopharma
Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Cancer

Most Recent Events

07 Aug 2024 US FDA approves IND application for WGc 043 in Epstein Barr (EB) virus related cancer
07 Aug 2024 WestGene Biopharma plans a phase I trial for Epstein Barr (EB) virus related cancer in USA and China
06 Aug 2024 The Center for Drug Evaluation (CDE) of the NMPA approves clinical trial application for WGc 043 in Epstein Barr (EB) virus related cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com